JPRN-UMIN000006459招募中2 期
Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer not harboring EGFR mutation who failed to prior treatment (TAILORED-2 study) - Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer not harboring EGFR mutation who failed to prior treatment (TAILORED-2 study)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Squamous cell carcinoma 2)Interstitial pneumonia or pulmonary fibrosis on chest CT scans 3) i)Brain metastasis expected bleeding ii)Patients with untreated Brain metastasis 4)Undergoing prior EGFR-TKI treatment 5)Active severe comorbidity disease. 6)History of hemoptysis 7)Uncontrollable hypertension 8)History of gastrointenstinal perforation or diverticulitis or fistula 9)Scheduled operation 10)History of grave drug allergic reaction. 11)Active concomitant malignancy 12)Pregnant or breast-feeding females 13)Inappropriate patients for this study judged by the physicians
研究者
相似试验
招募中
2 期
Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer harboring EGFR mutation who acquired resistance to prior gefitinib treatment (TAILORED-1 study)on-Small Cell Lung CancerJPRN-UMIN000006457Kyushu University30
尚未招募
2 期
A phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous Non- Small Cell Lung Cancer with brain metastasis and Harboring Epidermal Growth Factor Receptor Mutations.on-Small-Cell Lung CancerJPRN-UMIN000012514Department of Respiratory Medicine, Kumamoto University Hospital16
已完成
2 期
A phase II study of erlotinib plus bevacizumab in patients with performance status 2 to 3 and EGFR mutation-positive advanced non-small-cell lung cancerJPRN-UMIN000016507Shizuoka cancer center21
已完成
不适用
A phase II study of erlotinib plus bevacizumab in chemo-naive patients aged 75 or older with advanced non-squamous non-small-cell lung cancer harboring sensitive EGFR gene mutations(HSR1501)Advanced non-squamous non-small-cell lung cancerJPRN-UMIN000016904Department of Internal medicine, second division, Hamamatsu Univ. School of Medicine26
进行中（未招募）
不适用
A phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal carcinomas, refractory or intolerable to standard systemic therapyHistologically or cytologically verified upper gastro-intestinal carcinoma, including carcinomas of the esophagus, cardia, stomac, pancreas, gall bladder, and bile ducts of the following histological subtypes: adenocarcinoma, planocellular or squamous cell carcinoma, and anaplastic/high-grade or undifferentiated carcinomaEUCTR2006-001308-35-DKThe Finsen Center, Rigshospitalet63